Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Strikingly different atheroprotective effects of apolipoprotein A-I in early- versus late-stage atherosclerosis|
|Citation:||JACC: Basic to Translational Science, 2018; 3(2):187-199|
|Jamie Morton, Shisan Bao, Laura Z. Vanags, Tania Tsatralis, Anisyah Ridiandries, Chung-Wah Siu, Kwong-Man Ng, Joanne T.M. Tan, David S. Celermajer, Martin K.C. Ng, Christina A. Bursill|
|Abstract:||Preclinical studies have shown benefit of apolipoprotein A-I (apoA-I)/high-density lipoprotein (HDL) raising in atherosclerosis; however, this has not yet translated into a successful clinical therapy. Our studies demonstrate that apoA-I raising is more effective at reducing early-stage atherosclerosis than late-stage disease, indicating that the timing of HDL raising is a critical factor in its atheroprotective effects. To date, HDL-raising clinical trials have only been performed in aged patients with advanced atherosclerotic disease. Our findings therefore provide insight, related to important temporal aspects of HDL raising, as to why the clinical trials have thus far been largely neutral.|
|Keywords:||Atherosclerosis, cholesterol; high-density lipoproteins|
|Rights:||© 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.